Provided are methods, system and software for diagnosis, prediction and prognosis of a cancer patient based on the quantitative level of a set of biomarkers. Also provided is a database for the purpose of recording the quantitative level of a set of biomarkers.

Methods of treatment based on a breast cancer's biomolecule response to targeted treatment are provided. Expression levels of various biomolecules or histological assessment of infiltrating immune cells after initiation of human epidermal growth factor receptor 2 (HER2) targeted treatment can be used to determine whether a breast cancer will achieve a pathologic complete response. Based on likelihood of a pathologic complete response, a breast cancer can be treated accordingly.

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Provided are a composition for diagnosing breast cancer and a method of diagnosing breast cancer using the same. Breast cancer may be diagnosed using blood in a simple manner.

The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe.sup.2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.

Bufalin phosphate prodrugs are provided herein, as well as methods for their use as small molecule inhibitors of steroid receptor coactivator (SRC) family proteins. Methods for using bufalin phosphate prodrugs in treating or preventing cancer are also provided herein.

A method of obtaining and analyzing at least one tissue sample includes forming, in a tissue container, first tracking data associated with the at least one tissue sample. Second tracking data is formed, in a transport container. The second tracking data is associated with the at least one tissue sample. The at least one tissue sample is placed in the tissue container. The first and second tracking data from the tissue container and the transport container are scanned with an electronic scanning system to ensure that the first and second tracking data are both associated with the removed tissue sample.

In accordance with some embodiments herein, methods of determining signatures of HMGB1 isoforms in a subject are provided. In some embodiments, antibodies that bind specifically to HMGB1 isoforms are provided. In some embodiments, immunoassay kits are provided.

Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.

Embodiments of the disclosure include methods and compositions related to treating an individual for HER2+ positive cancer with an appropriate treatment based on outcome of a multiparameter classifier. The methods allow for identification of HER2+ individuals that are suitable to avoid chemotherapy, in specific embodiments. Methods of the disclosure also allow for identification of HER2+ individuals that should not avoid chemotherapy. In specific embodiments, the multiparameter classifier identifies whether there is (1) a ratio of HER2 amplification, relative to a control probe, of greater than or equal to 4.5; (2) a HER2 expression level score of 3+, as determined by immunohistochemistry, in at least 90% of breast cancer cells; (3) whether there is a HER2-enriched molecular subtype; and (4) whether the individual has a wildtype PIKC3A gene.